Not yet recruiting |
: VSV-hIFNbeta-NIS in Treating Patients With Stage IV or Recurrent Endometrial Cancer
: - Endometrial Clear Cell Adenocarcinoma
- Endometrial Mixed Adenocarcinoma
-
- Procedure: Biopsy Undergo imag
|
Recruiting |
: Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
: - Fallopian Tube Clear Cell Adenocarcinoma
- Fallopian Tube Endometrioid A
: 2016-07-29
: - Biological: Bevacizumab Given
|
Not yet recruiting |
: Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
: - Fallopian Tube Clear Cell Adenocarcinoma
- Fallopian Tube Endometrioid A
: 2016-07-20
: - Drug: Atezolizumab Given IV
|
Recruiting |
: Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
: - Fallopian Tube Clear Cell Adenocarcinoma
- Fallopian Tube Endometrioid A
: 2016-03-15
: - Drug: Carboplatin Given IV
|
Active, not recruiting |
: Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
: - Fallopian Tube Clear Cell Adenocarcinoma
- Fallopian Tube Endometrioid A
: 2010-02-23
: - Drug: Bortezomib Given IP
|
Active, not recruiting |
: Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
: - Fallopian Tube Clear Cell Adenocarcinoma
- Fallopian Tube Endometrioid A
: 2009-04-24
: - Drug: Elesclomol Sodium Given
|
Recruiting |
: Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
: - Fallopian Tube Clear Cell Adenocarcinoma
- Fallopian Tube Endometrioid A
: 2008-07-18
: - Behavioral: Behavioral Dietary Intervention
|
Completed |
: Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
: - Fallopian Tube Clear Cell Adenocarcinoma
- Fallopian Tube Endometrioid A
: 2005-12-06
: - Biological: Bevacizumab Given
|
Active, not recruiting |
: Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer
: - Fallopian Tube Clear Cell Adenocarcinoma
- Fallopian Tube Endometrioid A
: 2005-04-18
: - Other: Clinical Observation Un
|
Recruiting |
: Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery or Gynecological Cancers
: - Cervical Adenosarcoma
- Cervical Adenosquamous Carcinoma
- Cer
: 2013-12-19
: - Biological: Bevacizumab Given
|